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Abstract
Background: Clinical study reports (CSRs) have been increasingly utilised within academic research in recent years.
European Medicines Agency (EMA) Policy 0070 ‘Phase 1,’ which came into effect in January 2015, requires the
publication of regulatory documents such as CSRs from central applications in an anonymised format. EMA Policy
0070 requires sponsors to demonstrate careful consideration of data utility within anonymised CSRs published
within the scope of the policy, yet the concept of data utility is not clearly defined in the associated anonymisation
guidance.
Objective: To review the use of data from CSRs in published academic research and to hypothesise the potential
data utility of CSRs anonymised under the objectives of EMA Policy 0070 for future academic research.
Methods: Review of the objectives, research methodologies and findings of academic research reports using
unpublished data from CSRs (prior to EMA Policy 0070). Semi-structured interviews with authors of academic
research reports, including questions related to data utility of anonymised CSRs published under EMA Policy 0070.
Results: Thirteen academic research reports were identified and reviewed. The research purposes ranged from
assessment of reporting bias, comparison of methods and results with published data sources, detailed evaluation
of harms and adverse events, re-analysis and novel analyses including systematic reviews and meta-analysis. All of
the examples identified required access to the methods and results sections of CSRs (including aggregated
summary tables) and research purposes relating to evaluation of adverse events also required access to participant
narratives. Retaining anonymised participant narratives relating to interventions, findings and events, while
maintaining an acceptably low risk of participant re-identification, may provide an important gain in data utility and
further understanding of drug safety profiles.
Conclusions: This work provides an initial insight into the previous use of CSR data and current practices for
including regulatory data in academic research. This work also provides early guidance to qualitatively assess and
document data utility within anonymised CSRs published under EMA Policy 0070.
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Background
Clinical Study Reports (CSRs) represent a wealth of
information related to design, conduct and analysis of clin-
ical trials, in addition to more comprehensive trial results
compared to publicly available sources such as journal
manuscripts and clinical trial registries. Doshi et al. 2013
[1] refer to CSRs as a “hitherto mostly hidden and untapped
source of detailed and exhaustive data on each trial” and
make reference to the concept of a “compression factor,”
defined as the ratio of CSR page length compared to the
page length of the journal publication of the same trial, ran-
ging from 1 to 8805 based on the review of 78 CSRs [1].
Previous work has highlighted the impact of selective
outcome reporting [2, 3], in that the data and results
published within a journal manuscript may be incom-
plete or misleading, and the biases that originate from
this selective reporting. Increasingly, researchers under-
taking novel secondary analyses of clinical trial data such
as systematic reviews and meta-analyses are seeking ac-
cess to previously confidential regulatory documents,
such as CSRs. These documents are used as a means of
appraising, revaluating and reducing the impact of any
misreporting or selective reporting bias, generating more
complete and reliable information and investigating clin-
ical questions which could not have previously been
considered using published data sources alone [4–16].
The European Medicines Agency (EMA) policy on the
publication of clinical data for medicinal products for hu-
man use (EMA Policy 0070 ‘Phase 1’, herein referred to as
EMA Policy 0070), allowing global access to regulatory
documents for non-commercial purposes, came into effect
in January 2015. The policy requires ‘clinical reports’ (de-
fined as clinical overviews, clinical summaries, and CSRs
together with the following appendices to the CSRs: proto-
col and protocol amendments, sample case report form
and documentation of statistical methods (clinical trial
statistical analysis plan (SAP)) from central regulatory ap-
plications to be published in an anonymised portable
document format, such that the risk of re-identification of
trial participants from the information available contained
within these documents, including any retained narrative
information relating to individual participants, is deemed
to be acceptably low for public disclosure of data [17].
The concept of ‘Data Utility’ appears to be an important
criterion for anonymised CSRs to meet the objectives of
EMA Policy 0070. Reference is made within several sections
of EMA Policy 0070 anonymisation external guidance and
within the ‘Anonymisation Report’ template that the appli-
cant must demonstrate careful consideration of “the impact
of the anonymisation methodology used on data utility
[17].” However, despite the apparent importance of this
criterion, the EMA Policy 0070 external guidance [17] does
not define or quantify the utility of anonymised CSRs (and
“Data Utility” is absent within section “3. Definitions”) [17].
The Organization for Economic Co-operation and Devel-
opment (OECD) propose the following definition for ‘Data
Utility’: “A summary term describing the value of a given
data release as an analytical resource. This comprises the
data’s analytical completeness and its analytical validity.
Disclosure control methods usually have an adverse effect
on data utility. Ideally, the goal of any disclosure control re-
gime should be to maximise data utility whilst minimising
disclosure risk. In practice disclosure control decisions are a
trade-off between utility and disclosure risk [18].”
Clearly, the ‘analytical completeness and analytic valid-
ity’ of anonymised CSR data, and therefore the relative
‘data utility’ of anonymised CSRs made public under EMA
Policy 0070 are directly dependent on the consumers of
the data and their reasons or purposes for using this data.
Therefore the objective of this work is to review the
previous use of data from CSRs in academic research
and with these research purposes in mind, to hypothe-
sise the potential data utility of CSRs anonymised under
the objectives of EMA Policy 0070.
Methods
This paper begins with a short reflection of requests
made under EMA Policy 0043, a policy which enables
requests for access to regulatory documents (related to
medicinal products for human and veterinary use),
followed by a summary and discussion of previous re-
search conducted using CSR data [4–16].
Insights from EMA policy 0043
An EMA Policy on access to documents (related to medi-
cinal products for human and veterinary use), known as
‘EMA Policy 0043’, came into effect in 2010. Requesting
documents through EMA Policy 0043 is a controlled
process and requesters must identify themselves and their
affiliation but it are not required to document the purpose
of their request as part of the requesting process. Figure 1
summarises the number of requests and number of pages
released per affiliation and was made public in 2016 [19].
Source: Annexes to the annual report of the European
Medicines Agency 2016, Annex 19 [19].
1. ‘Legal’ and ‘Consultant’ requesters refers to mostly
professionals from or contracted by the
pharmaceutical industry. The category
“Pharmaceutical industry” both includes companies
from the innovative and generic industry; no
distinction was made.
2. The request process of EMA Policy 0043 includes
an appeal process in the case of an initial rejection
It should be noted that the scope of EMA Policy 0043 is
not limited to requests for clinical reports (i.e. CSRs and
other documents related to clinical trial conduct and results
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(such as clinical trial protocols and SAPs) and a range of
other documents such as commercial, technical or legal
documents as well as meeting minutes could also be re-
quested. A breakdown of the information within Fig. 1 re-
lating to the type of documents requested was not available.
Grouping together the first seven rows to represent
‘Non-commercial’ requests from “Not-for-profit organ-
isation” to “Academia/Research institute”, the number of
requests received represent 18.6% of total requests and
‘Commercial’ requests from ‘Legal’, ‘Pharmaceutical In-
dustry’ and ‘Consultant’ represents 76% of total requests.
However, when comparing the number of pages re-
leased, the ‘Non-Commercial’ and ‘Commercial’ groups
are approximately equivalent with 52.3 and 45.6% re-
spectively. This shift is mainly explained by requests for
documents with a large number of pages (likely to be
clinical reports such as CSRs, trial protocols, trial SAPs)
by Academia/Research institutes (31.59%) while other
subgroups may be more likely to request other docu-
ments (such as technical documents or meeting mi-
nutes) that represent fewer pages. It is also of note that
requests from “Patients or Consumers” represent 6.68%
of all requests and 9.55% of pages released.
We note that direct extrapolation of these figures from
EMA Policy 0043 (a controlled process covering all types
of documents) to EMA Policy 0070 (public access to
clinical reports as part of a central application) is not
recommended and the type of documents requested by
each consumer group via EMA Policy 0043 is merely an
assumption. Nonetheless, the affiliations described
within Fig. 1 provide an indication of who the main data
consumers of EMA Policy 0070 may be and further
research on EMA Policy 0043 requests, particularly re-
lating to the types of documents requested by each data
consumer group, could help in understanding the likely
consumers of EMA Policy 0070 and their purposes.
Results
Use of clinical study reports in academic research
A number of examples of journal publications using CSRs
in academic research [4, 8–11, 14, 15] were cited within a
conference presentation delivered by Tom Jefferson in 2017
[20] and within a related published report in 2018 [21].
This section summarises and discusses the research pur-
poses and methodology applied within these examples, in
addition to a recently published Cochrane Review involving
SJN which has made use of CSR data in analysis [16].
Some of the research objectives from these examples,
outlined in general terms including the sections of the
CSRs that may be required for the research, are sum-
marised in Table 1. We further discuss some of the re-
search objectives outlined within the examples within this
section. Further specific details of the all regulatory data
sources provided for the research, the methods employed
within each example and the main findings of the research
are summarised in Additional file 1: Table S1.
Fig. 1 Policy 0043 documents requests per affiliation
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We note that many of the research purposes outlined in
Table 1 overlap and are not intended to be an exhaustive
list; rather a general summary of a sample of published re-
search using CSR data at the time of writing. It must be
noted that the examples discussed within this section are
a ‘selective sample’ of academic work which has mostly
shown changes in conclusions, particularly regarding
harms of drugs, when analysing or re-analysing clinical
trial data using CSRs and the methodological approaches
taken by some of the academic research groups have been
challenged by the pharmaceutical companies in question
(see Additional file 1: Table S1). This sample should not
be considered completely reflective of academic objectives
for accessing regulatory documents or a comprehensive
list of all research using CSRs (which is likely much wider
as indicated by the number of requests from Fig. 1) The
selective nature of the sample summarised here must be
taken into account when interpreting the findings within
the context of all published research making use of
unpublished regulatory documents.
Assessment of reporting and evaluation of bias
A common reason for using unpublished information,
such as the trial protocols and CSRs of specific trials to
access to detailed trial methodology and comprehensive
results, is to perform an appraisal, assessment and evalu-
ation of any bias in the trial design, misreporting or any
selective outcome reporting bias in journal manuscripts
[2, 3]. It is recommended within the Cochrane Handbook
for Systematic Review of Interventions that selective out-
come reporting should be appraised within Cochrane
Reviews by comparing trial protocols with published re-
ports [23] and examples identified within this review
have also shown the use of CSRs for identifying misre-
porting or selective outcome reporting.
For example, by comparing the information in CSRs
and other regulatory documents (such as protocols) to
journal publications for 20 trials of Gabapentin, Vedula
et al [15] identified selective outcome reporting for trials
of off-label use of gabapentin which ‘threatens the valid-
ity of evidence for the effectiveness of off-label interven-
tions’. Eyding et al [4] also discovered that published
data overestimated the benefit of reboxetine versus
placebo by up to 115% and reboxetine versus SSRIs by
up to 23%, and also underestimated harm compared to
the information presented in CSRs and other regulatory
documents. Similarly, by comparing publications of Orli-
stat trials to their corresponding CSRs, both Schroll et al
[9] and Hodkinson et al [10] identified that journal pub-
lications provided ‘insufficient’ information on harms
outcomes of clinical trials and in some cases the authors
noted ‘important disparities’ in the definitions and num-
bers of adverse events were reported across different
documents relating to the same trial.
Detailed evaluations of harms and adverse events
It is mandatory that a summary of adverse events (AEs)
occurring during a trial is made public via registries such
as ClinicalTrials.gov or EudraCT [24]. However, a num-
ber of examples have made use of the more detailed
harms and AE information available within CSRs, both
in the context of appraising ‘selective outcome reporting’
as outlined in the section above [4, 9–11, 15] as well as
for novel analyses of previously unpublished harms and
AE information [11–14].
For example, Maund et al [12, 13] present methodo-
logical investigations relating to the conclusions that can
be drawn from reading summary tables of AEs which are
usually dictionary coded, compared to reading verbatim
descriptions in the narratives. Their illustrative example of
Table 1 Examples of the objectives of research using CSR data
Objective CSR section(s) that may be required Examples
Assessment of reporting and evaluation
of bias
Methods, results (aggregate summary
tables and text), narratives, participant
listings
Eyding et al [4], Schroll et al [9], Hodkinson et al [10],
Jefferson et al [11], Vedula et al [15]
Comparison of methods and/or results
(including adverse events) with data
registries or manuscripts
Methods, results (aggregate summary
tables and text)
Eyding et al [4], Le Noury et al [8], Schroll et al [9], Hodkinson
et al [10], Jefferson et al [11], Maund et al [12–14], Vedula
et al [15], Nevitt et al [16]
Detailed evaluation of harms and
adverse events
Results (aggregate summary tables
and text), narratives, participant listings
Eyding et al [4], Maund et al [12–14]
Systematic review and meta-analysis
(evidence synthesis)
Methods, results (aggregate summary
tables and text), narratives
Eyding et al [4], Jefferson et al [11],
Maund et al [14], Nevitt et al [16]
Re-analysis (repeating original analysis) Methods, results (aggregate summary
tables and text), narratives, participant
listings
Le Noury et al [8] (also using individual participant data)a
Re-analysis (different method or
objective to the original analysis)
Methods, results (aggregate summary
tables and text), narratives, participant
listings
Maund et al [14], Nevitt et al [16]
aIn this example, Le Noury et al [8], re-analysis was conducted using both individual participant data (IPD), requested via data sharing platform
clinicalstudydatarequest.com [22] in addition to supporting information from CSRs and case report forms
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nine trials of duloxetine for the treatment of major depres-
sive order shows that coded events and narratives within
CSRs suggest different numbers of events related to sui-
cide and the authors conclude that in this case the narra-
tives are more informative and coded events in summary
tables may be misleading and may not fully capture the
true nature of the event. Specifically:
“…narratives of adverse events can provide additional
information, including original investigator reported ad-
verse event terms, which can enable a more accurate esti-
mate of harms [13].”
“Using the patient’s trial identification number we were
able to reconcile data reported in the patient listings with
those in the narrative. Secondly, using data (treatment as-
signment, coded term, and timing of event) from the patient
listings and narratives, we were able to reconcile data from
these two formats with the data in summary tables [13].”
A related publication from Maund et al [14], presents a
meta-analysis relating to the benefit and harms of duloxe-
tine for the treatment of stress urinary incontinence, with a
specific interest in harms related to suicide and violence, in
response to FDA concerns about an association between
duloxetine and these serious adverse events. The authors
use data from CSRs (summary tables and narratives) to per-
form meta-analysis of four trials and compare their analysis
to the results of a Cochrane review of the same topic con-
ducted only with data available in the public domain (i.e.
from trial publications). The two pooled analyses come to
the overall same conclusion that clinical benefits of duloxe-
tine for stress urinary incontinence do not outweigh the po-
tential harms, but the two analyses consider different
outcomes sets and show slightly different results for com-
mon outcomes. Notably, the authors note that the analysis
of CSR data has allowed more detailed considerations of
specific AEs which would not have been possible without
access to CSRs and narratives.
For example, “one patient had a “nervous breakdown,”
which was coded as mental disorder, and another patient
reported “feeling drugged,” which was coded as somnolence.
In addition, 5 patients, all receiving duloxetine, experienced
a total of 8 events that were mentioned only in the narrative
text [14].”
These publications highlight the potential utility of the
participant narratives and participant listings for novel ana-
lyses relating to AEs and further understanding of drug
safety profiles beyond summary statistics of dictionary-
coded events. It must be noted that participant listings are
out-of-scope for ‘Phase 1’ of EMA Policy 0070 and work
conducted in November 2017 showed that the majority of
CSRs published under EMA Policy 0070 have ‘fully redacted’
participant narratives [25], likely due to concerns regarding
the risk of re-identification from narrative information relat-
ing to a specific participant and technical challenges to
retrospectively anonymise unstructured data (i.e. narratives
and body text), despite EMA Policy 0070 external guidance
specifying that case narratives should be anonymised rather
than removed [17]. With the valid re-identification concerns
in mind, primarily, the ability to follow the ‘journey’ of a par-
ticipant through a trial, particularly preserving sequences
and distances between interventions, findings and events
(and access to different definitions of events, including inves-
tigator reported terms) has clear advantages for the ‘utility’
of CSR data and is essential for detailed evaluations of harms
outcomes, such as in the examples of Maund et al [12–14].
Secondarily, availability of demographics and medical history
among others could also support more detailed analyses, in-
cluding analyses relating to harms and AEs.
Use of previously unpublished summary data for
systematic reviews and meta-analyses
Previous work has shown that publicly available informa-
tion (such as from journal publications and trial registries)
of primary and secondary outcomes, as well as patient-
relevant outcomes and harms, may not be sufficient [5–7,
11, 16], particularly for the objectives of a novel systematic
review or meta-analysis [11, 16]. Additionally, the format
that the summary results are provided in may not readily
allow the inclusion of the information within meta-
analysis; for example, where a measure of precision of the
treatment effect is not published or if numerical results
are not reported for all measurement times [16].
Therefore, in order to provide the most clinically inform-
ative and high quality systematic review and meta-analysis
results as possible, researchers may wish to use unpublished
summary (aggregated) data from one or more CSRs within
systematic reviews and meta-analyses. In 2014, Jefferson
et al [11, 27, 28] reported on the first Cochrane review to be
based on all relevant full CSRs of a drug (oseltamivir), aug-
mented by ‘regulatory comments’ (i.e. any other relevant in-
formation submitted to regulatory authorities for
oseltamivir).
A CSR would typically contain more details about the
choice of statistical method, interpretation of results and
the full set of endpoints, results and statistics at all time
points measured and therefore may provide a useful sup-
plementary source of data for systematic reviews and meta-
analysis. For example, a review of 101 CSRs conducted by
Wieseler et al [5] shows that CSRs provided complete infor-
mation on 78 to 100% of benefit outcomes (compared to
20 to 53% from publicly available sources), CSRs also pro-
vided considerably more information on harms and on
patient-relevant outcomes such as outcomes describing
morbidity, mortality, and health-related quality of life.
Use of regulatory data in Cochrane reviews: current
practice and attitudes
A survey was conducted among Cochrane authors between
June and September 2016 regarding any experiences and
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opinions they had of using CSRs and ‘other regulatory doc-
uments’ (defined as any document produced by or held by
a regulatory agency) in Cochrane Reviews [20, 21, 29].
There were 156 respondents out of 7181 invited
Cochrane authors who had worked on a Cochrane review
in the previous 2 years (around 2% response rate). Results
of the survey showed only 10% of the 156 respondents
used or requested regulatory data (mostly CSRs to supple-
ment meta-analyses) from pharmaceutical companies dir-
ectly or from regulatory agencies such as the EMA and
the FDA. A further 5% had considered using regulatory
data and the remaining 85% had not considered using
regulatory data. Of those who had experience of using or
requesting regulatory data, 80% believed that regulatory
data should be used on Cochrane reviews, yet two thirds
of these respondents who had accessed and included CSR
data in Cochrane reviews mentioned barriers to using this
data such as limited or restricted access to the data (such
as not being able to print documents and download data)
and lack of experience or skills required to interpret these
detailed documents [29].
The proportion of individuals who believed that regula-
tory data should be used in Cochrane Reviews falls to 38
and 32% respectively for those who had considered or had
not considered using regulatory data and results of the
survey also showed that out of all respondents, only 12%
claimed to know where to access regulatory information
from clinical trials and 32% of respondents admitted to
having no understanding of regulatory submissions and
the documents produced for this process [29].
These results demonstrate that using regulatory data,
such as the data from CSRs is rather new for the academic
Cochrane community as a whole but researchers who are
requesting or using regulatory documents to complete
Cochrane Reviews consider access to these documents im-
portant and valuable for their analyses. Results of the sur-
vey also suggested that the availability of further guidance
on how to interpret and use regulatory data in secondary
analyses would help to promote the use of CSRs in
Cochrane Reviews [29]. Conference proceedings have
been presented regarding advantages and disadvantages in
using CSRs versus published articles for Cochrane reviews,
highlighting the extra information and opportunities of
such data sources as well as challenges working with CSRs
for Cochrane authors [30, 31]. Guidance of when to use
Clinical Study Reports and other regulatory documents in
systematic reviews has been developed as part of a
‘Cochrane Methods Innovation Fund’ [21].
Potential impact of EMA policy 0070 on data utility of
CSRs: academic author interviews
The examples considered within this review are based on
CSRs and other regulatory documents (such as protocols,
case report forms etc.) that were gathered before the im-
plementation of EMA Policy 0070.
In order to further explore the use of CSRs in the pro-
jects and the potential impact that EMA Policy 0070
may have on the data utility of anonymised CSRs in aca-
demic research, in August to September 2017, we
attempted to make contact with the authors of the jour-
nal publications identified and discussed within this re-
view (Table 1 and Additional file 1: Table S1). Full
details of the correspondence with authors who
responded to us is provided in Additional file 2, shared
with the permission of the authors.
In summary, all of the authors stated that their ana-
lyses would not have been possible without access to
CSRs. None of the authors raised any specific concerns
about anonymised or redacted CSRs (in line with EMA
Policy 0070). In fact, one research team had used CSRs
publicly available from a sponsor website which were
redacted and this redaction did not impact upon the
analysis from the author’s recollection [8]. Furthermore,
none of the authors stated that their team had any diffi-
culties in interpreting the information from the CSRs (a
potential barrier raised within the Cochrane Survey) [20,
29]; the only problems related to ‘illegible’ text or the
portable document format of the documents which pre-
vented electronic searching.
All of the authors stated that some or all of their ana-
lyses or research would not have been possible if narra-
tives and/or appendices (with participant listings) were
removed from anonymised CSRs under EMA Policy 0070.
One author stated that: “Anonymised CSRs are ok, but the
current EMA policy redacts important information about
when the adverse events appeared as well as what they
were. Newer CSRs do not have individual adverse event
listings and the EMA are not even in possession of them.”
Another author stated that: “I have actually looked at
data that are released under the EMAs new EMA Policy
0070, and they do provide fully redacted CSRs. So yes, I
would say you could use these provided the drug is centrally
licenced. But redactions may permit what data can be used,
and they may not be of use for creating IPD datasets with-
out the subject IDs and other patient-level information.”
It should be emphasised that these observations are
anecdotal and rhetorical as these projects were based on
CSRs that were obtained before the implementation of
EMA Policy 0070. We must also note that the quotes
above reflect the opinions of the authors and we have
not verified the accuracy of any statements made by the
authors. However, our observations as well as the obser-
vations and views of the academic authors, and the ratio-
nales for the type of analyses being conducted using
CSRs do raise some potential issues relating to ‘data util-
ity’ of documents anonymised under EMA Policy 0070
(Phase 1). The full extent and any impact of such issues
Ferran and Nevitt BMC Medical Research Methodology          (2019) 19:204 Page 6 of 10
will not become apparent until sufficient research pro-
jects are conducted and published using anonymised
CSRs prepared in line with EMA Policy 0070.
Discussion
Summary of findings and implications
CSRs have previously been considered as an ‘untapped’
source of detailed information relating to design, con-
duct and analysis of clinical trials [1]. The value of the
information within CSRs is becoming increasingly recog-
nised within the academic research community, particu-
larly within the Cochrane Collaboration [20, 21, 29].
Publicly available summary data of clinical trial results
from journal publications and trial registries may be
suitable and sufficient to support some types of second-
ary analyses. However, an anonymised CSR provides
complete information and data on study design and stat-
istical methods, interpretation of results and the full set
of endpoints’ results and statistics. Such a resource
would certainly allow a more in depth appraisal includ-
ing verification of numerical results, detailed assessment
relating to bias such as selective outcome reporting and
the conduct of novel analyses, such as systematic reviews
and meta-analyses using data from all endpoints.
EMA Policy 0070 ‘Phase 1’, where anonymised CSRs
are made public, is likely to further facilitate the second-
ary use of the information within CSRs for appraisal and
secondary analysis. However, little consideration has
been given to the data utility of the anonymised infor-
mation within CSRs under EMA Policy 0070. The ob-
jective of this review was to investigate the type of
research purposes and research methodologies employed
in previous work using data from CSRs in academic re-
search, and to hypothesize the impact of EMA Policy
0070 on the ‘data utility’ of future research of this kind.
Based on the number of requests made under EMA Pol-
icy 0043, we anticipate that academic researchers or re-
search groups and the Pharmaceutical Industry are likely
to be the primary recipients of anonymised CSRs under
EMA Policy 0070. The research examples we discuss
within this review indicate that the objectives and scopes
of secondary analyses and novel research that have been
conducted using CSR data are vast (Table 1, Additional
file 1: Table S1). Authors of such research have communi-
cated with us their concerns over the type of research that
could be conducted in the future if information such as
participant listings or narratives are redacted or removed
completely under EMA Policy 0070 (Additional file 2).
Keeping the same conclusions and comparable numer-
ical results of all primary, secondary and safety endpoints
in the Anonymised CSRs to those of the original CSR
(prior to any anonymisation) is of utmost importance.
There are examples in the literature on how narratives are
used to verify safety conclusions (see Additional file 1:
Table S1). Handling of narratives, together with the hand-
ling of in-text listings, seems to be the most challenging
aspect of EMA Policy 0070 from a technical standpoint
and various levels of or approaches to anonymisation
would further define different levels of data utility.
Certain free-text fields such as e.g. Adverse Events Re-
ported Terms has been shown to be instrumental for
certain secondary analysis to e.g. verify dictionary coding
and conduct re-analysis [12–14]. Further, preserving
Subject IDs and Dates in an anonymised format in order
to follow the events of a participant, using sequences
and distances to further understand the drug safety pro-
file. An ongoing review of CSRs published under EMA
Policy 0070 indicates that free-text variables (such as
narratives) tend to be fully redacted when a dictionary-
coded variable is available and deemed to be better
suited for analysis [25]. The PhUSE De-Identification
standard [32] recommends as a primary rule in the case
of pro-active release of data to follow such rational and
a secondary rule to “Review and redact PII” in such free-
text variables. It is therefore advised to researchers to
make it clear in their requests in the context of their re-
search objective whether certain free-text variables (with
all PII redacted) are required, even if a dictionary-coded
variable is available in the given data domain.
Two main general types of analysis emerged from this
research: Appraisal and Secondary Analysis. The different
objectives across these two general analysis types should
help prioritise anonymisation methods from a data utility
perspective in addition to data privacy considerations. The
classification of research objectives also provides more
guidance for developing a qualitative approach to assess
and document data utility of anonymised CSRs in-line
with EMA Policy 0070 [17], Health Canada Public Release
of Clinical Information Policy [33] or other contexts.
Further understanding of the safety profile of the drugs
and verification of how conclusions of clinical studies are
derived would certainly provide added value for many
stakeholders and data consumers, including patients them-
selves. However, several journal publications that were
reviewed within this review and described in Additional file
1: Table S1 have had their findings challenged by the spon-
soring pharmaceutical companies through comments on
journal websites. Discussion of academic findings and in-
terpretations should always be encouraged but there is a
risk that ‘rapid-response’ additional analyses as a challenge
to published research may confuse readers and secondary
data consumers such as clinical practitioners, patients and
patient associations who cannot interpret which of the
many published results are the ‘correct’ ones. Bonini et al.
2014 [34] also note that “access to clinical data imposes a
high ethical standard on anyone using those data, lest in-
appropriate reanalyses breed unjustified concern about the
efficacy or safety of marketed drugs.” We (SJN and JMF) are
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of the opinion that communication (and potentially collab-
oration) between academic research groups and pharma-
ceutical companies regarding interpretations of regulatory
documents such as protocols, statistical analysis plans and
CSRs, and the interpretation of results of secondary ana-
lyses from their different perspectives during the research
projects should be encouraged. Such communication and
discussions occurring before any results of secondary ana-
lyses are published within journals are likely to provide the
most informative novel results and in turn, provide the
most benefit to readers and data consumers.
Limitations and future considerations
It must be emphasised that the examples of academic re-
search using CSRs summarised within this review (Table
1 and Additional file 1: Table S1) are a selective sample
and do not necessarily represent all research objectives
which would make use of anonymised CSRs under EMA
Policy 0070. Further, most observations provided to us
by the authors of this research and our interpretations
are rhetorical and speculative, rather than based on dir-
ect experience of anonymised CSRs published under
EMA Policy 0070 and the validity of these observations
may not become clear for some time.
The planned ‘Phase 2’ of EMA Policy 0070 which ex-
tends to sharing of individual participant data (IPD)
should provide the next level of data utility that is required
to conduct robust secondary analyses. A number of spon-
sors already provide access to anonymised IPD via data
sharing platforms [22, 26] based on research requests for
studies under the European Federation of Pharmaceutical
Industries and Associations (EFPIA) principle of respon-
sible clinical trial data sharing [35]. ‘Phase 2’ of EMA Pol-
icy 0070, when in effect, should in principle standardise
the access to anonymised IPD for studies part of a central
application in European Union regardless of the outcome
of the application. The current needs of the research com-
munity which may include access to individual participant
information such as full patient listings, which is out of
scope of EMA Policy 0070 ‘Phase 1’, will be better ad-
dressed in ‘Phase 2’ of the policy where Individual Patient
Datasets are in scope.
In the context of EMA Policy 0070, where anonymised
CSRs are made public, a myriad of data recipient groups
could be considered together with various objectives for
reviewing and using the information within these anon-
ymised CSRs. Their needs could differ from the academic
research community and could be worth investigating at a
later point.
In addition, at the time of writing, other regulatory
agencies are defining, finalising and publishing their data
transparency initiatives. FDA made an announcement in
January 2018 [36] and started pilots with pharmaceutical
companies where redaction is the only anonymization
method and full listings of participant narratives are out-
of-scope [37]. Health Canada started developing regula-
tions around public access to clinical documents in 2017
and released a draft guidance for review in the second
quarter of 2018 [33]. Difference of requirements between
EMA Policy 0070 guidance, FDA and Health Canada ap-
proaches (under development) [38] may also lead to dif-
ferent anonymized versions of the same document in the
public domain. Only when all policies are finalised will it
become clear which versions under which jurisdiction
serve best the needs of the academic community and
others.
Conclusions
In conclusion, EMA Policy 0070 guidance [17] refers to
various levels of anonymisation but based only on level
of risk of re-identification of participants without refer-
ence to different levels of data utility. The extent of the
data utility of CSRs published under EMA Policy 0070
for academic research may not be fully known for some
time, therefore in this interim time period, this review
provides an initial insight into the previous use of CSR
data, current practices for including regulatory data in
academic research such as Cochrane systematic reviews
and some early indications for the potential use of the
data, and therefore the utility of anonymised data, from
CSRs published under EMA Policy 0070.
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